ReviewInternational journal of molecular sciences2019
Immune and Inflammatory Cells in Thyroid Cancer Microenvironment.
Review in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 174 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
174 citing papers in PubMed, 3 syntheses or guidelines pooled it, 234 citations in OpenAlex.
- A bibliometric analysis of inflammation and thyroid carcinoma: research trends and future perspectives.Frontiers in oncology · 2025Pooled it
- Emerging insights into thyroid cancer from immunotherapy perspective: A bibliometric analysis.Human vaccines & immunotherapeutics · 2024Pooled it
- The relationship between thyroid peroxidase antibody and differentiated thyroid cancer: a systematic review and meta-analysis.Frontiers in endocrinology · 2024Pooled it
- Recent Advances in the Treatment of Thyroid Pathologies with Selenium-Containing Compounds, Nanoparticles and Nanocomplexes Based on Selenium and Selenoproteins.Biological trace element research · 2026Review
- Convergent Mechanistic Pathways Driving the Anaplastic Phenotype in Thyroid Cancer.International journal of molecular sciences · 2026Review
- Review
- Article
- Article
- Integrated Cytokine, Metabolic, and Proliferative Profiling Reveals Divergent Metabolic and Proliferative Responses in Papillary Thyroid Cancer Cells.International journal of molecular sciences · 2026Article
- Prognostic value and therapeutic potential of the cuproptosis-related gene LOXL2 in thyroid cancer.Translational oncology · 2026Article
- Exploratory Machine Learning and Omics Integration in the Search for Biomarkers of Papillary Thyroid Cancer.Biology · 2026Article
- Pre-RAI Monocyte-to-Lymphocyte Ratio Predicts Early and Higher Recurrence Risk in Intermediate-Risk DTC, While PNI and NRI Show No Prognostic Value.Clinical endocrinology · 2026Article
- Integrative Bioinformatics Analysis Reveals COL13A1 and COL23A1 as Potential Diagnostic and Prognostic Biomarkers in Thyroid Cancer.Health science reports · 2026Article
- Piezo channels in tumors.Journal of cancer research and clinical oncology · 2026Review
- Transcriptome and experimental validation identify prognostic genes associated with lipotoxicity in thyroid carcinoma.BMC cancer · 2026Article
- Interpretable LightGBM model with SHAP analysis predicts non-excellent response to initial radioiodine therapy in differentiated thyroid carcinoma.Journal of applied clinical medical physics · 2026Article
- Evaluation of three inflammation-associated blood indices for predicting malignancy in thyroid nodules.Archives of endocrinology and metabolism · 2026Article
- Review
- Tumor microenvironment-guided targeted and immunotherapy in anaplastic thyroid cancer: a literature review from preclinical models to clinical translation.Translational cancer research · 2026Review
- Thyroid Cancer in the Modern Era: From Molecular Landscape and Multimodal Diagnostics to Integrative Traditional Chinese Medicine-A Comprehensive Review.Cancer management and research · 2026Review
114 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A hallmark of cancer is the ability of tumor cells to avoid immune destruction. Activated immune cells in tumor microenvironment (TME) secrete proinflammatory cytokines and chemokines which foster the proliferation of tumor cells. Specific antigens expressed by cancer cells are recognized by the main actors of immune response that are involved in their elimination (immunosurveillance). By the recruitment of immunosuppressive cells, decreasing the tumor immunogenicity, or through other immunosuppressive mechanisms, tumors can impair the host immune cells within the TME and escape their surveillance. Within the TME, cells of the innate (e.g., macrophages, mast cells, neutrophils) and the adaptive (e.g., lymphocytes) immune responses are interconnected with epithelial cancer cells, fibroblasts, and endothelial cells via cytokines, chemokines, and adipocytokines. The molecular pattern of cytokines and chemokines has a key role and could explain the involvement of the immune system in tumor initiation and progression. Thyroid cancer-related inflammation is an important target for diagnostic procedures and novel therapeutic strategies. Anticancer immunotherapy, especially immune checkpoint inhibitors, unleashes the immune system and activates cytotoxic lymphocytes to kill cancer cells. A better knowledge of the molecular and immunological characteristics of TME will allow novel and more effective immunotherapeutic strategies in advanced thyroid cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.